Can Allostery Be a Key Strategy for Targeting PTP1B in Drug Discovery? A Lesson from Trodusquemine

Area of Science:

• Biochemistry and Molecular Biology
• Pharmacology
• Drug Discovery

Background:

• Protein tyrosine phosphatase 1B (PTP1B) is a key enzyme in signaling pathways linked to obesity, diabetes, cancer, and neurodegeneration.
• Inhibiting PTP1B offers a therapeutic strategy for these pathologies.
• Allosteric inhibition presents an advantage over catalytic site-directed inhibition for PTP1B drug development.

Purpose of the Study:

• To review the therapeutic potential of trodusquemine as an allosteric PTP1B inhibitor.
• To explore the correlation between trodusquemine's activities and PTP1B inhibition.
• To examine aminosterol analogues and structure-activity relationships for novel PTP1B inhibitor discovery.

Main Methods:

• Literature review of preclinical and clinical studies on trodusquemine.
• Analysis of trodusquemine's mechanism of action as a non-competitive PTP1B inhibitor.
• Examination of structure-activity relationships of related aminosterol compounds.

Main Results:

• Trodusquemine, a natural aminosterol, acts as a non-competitive inhibitor of PTP1B.
• Trodusquemine exhibits diverse therapeutic effects, including antidiabetic, anti-obesity, anti-cancer, and neuroprotective properties.
• These activities are linked to its PTP1B inhibitory function.

Conclusions:

• Trodusquemine is a significant milestone in the development of allosteric PTP1B inhibitors.
• Its broad therapeutic potential warrants further investigation for various human diseases.
• Aminosterol analogues offer a promising avenue for discovering new PTP1B-targeting drugs.